Inactive Instrument

News Arix Bioscience plc

Stocks

ARIX

GB00BD045071

Investment Management & Fund Operators

All News

13/02/24	RTW Biotech Opportunities Ltd a fund managed by RTW Investments, LP completed the acquisition of Arix Biosciences Plc's assets from Arix Bioscience plc.	CI
12/02/24	Arix Bioscience's Asset Sale to RTW Biotech Takes Effect	MT
12/02/24	Arix Bioscience shares suspended ahead of RTW takeover	AN
12/02/24	Arix Bioscience Shares to be Suspended on London Exchange Amid Acquisition	MT
29/01/24	Arix Bioscience Shareholders Approve Asset Sale to RTW Biotech	MT
23/01/24	Arix Bioscience Gains UK Regulatory Approval for Sale to RTW Biotech	MT
22/01/24	RTW Biotech Buys Minority Stake in Arix Bioscience to Support Planned Takeover	MT
22/01/24	Arix Bioscience plc Announces Resignation of Directors	CI
19/01/24	Arix Bioscience eyes USD19 million return from Harpoon sale	AN
19/01/24	Rtw Biotech Opportunities Operating Ltd completed the acquisition of a 26.6% stake in Arix Bioscience plc from Acacia Research Corporation for £47.2 million.	CI
09/01/24	Arix Bioscience's Portfolio Company Signs $680 Million Takeover Deal with Merck & Co.	MT
08/01/24	Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. for $410 million.	CI
08/12/23	Arix Bioscience's Portfolio Company Doses First Patient in Late-stage Trial of Choroidal Melanoma Therapy	MT
01/12/23	RTW Biotech Opportunities Ltd a fund managed by RTW Investments, LP agreed to acquire Arix Biosciences Plc's assets from Arix Bioscience plc for £190 million.	CI
01/11/23	RTW Biotech agrees "immediately accretive" Arix Bioscience takeover	AN
01/11/23	RTW Biotech Opportunities, Arix Bioscience Agree on Potential Merger Terms	MT
01/11/23	Rtw Biotech Opportunities Operating Ltd enter into an agreement to acquire 26.6% stake in Arix Bioscience plc from Acacia Research Corporation for £47.2 million.	CI
27/09/23	Arix Bioscience plc, H1 2023 Earnings Call, Sep 27, 2023
27/09/23	Arix Bioscience CEO to Depart	MT
27/09/23	Arix Bioscience plc Reports Earnings Results for the Half Year Ended June 30, 2023	CI
27/09/23	Arix Bioscience plc Announces Resignation of Robert Lyne as Chief Executive Officer, by the End of 2023	CI
07/08/23	Arix Bioscience reports dip in portfolio value in July	AN
13/07/23	Arix Bioscience launches strategic review despite value increase	AN
28/06/23	Evommune, Inc. announced that it has received $57.5 million in funding from a group of investors	CI
23/06/23	Arix Bio portfolio company Disc raises USD157.8 million	AN